Personalized Drug Formulations

Abstract submission deadline

closed (31 October 2024)

Manuscript submission deadline

31 January 2025

Viewed by

2663

Topic Information

Dear Colleagues,

Personalized medicine, also known as precision medicine, represents a flourishing field of research in the medical and pharmaceutical fields. It refers to the customization of medical treatments to the individual characteristics, needs, and preferences of each person and the choice of appropriate therapies for specific groups of patients affected by the same disease. This approach overcomes the concept of “one-size-fits-all” by proposing the administration of the “right drug” in its “right quantity” for the “right patient” at the “right time”. To achieve this goal, there is a need to develop novel medications tailored to the patient’s condition, which they can be termed as “personalized drug formulations”.

This topic covers any aspect related to the tailored drug therapy regarding formulations and dosage forms in a multidisciplinary context.

We are pleased to invite you to contribute to this topic, which aims to highlight the latest advances in personalized drug formulations, with particular emphasis on innovative approaches that address the current challenges in this research area. All manuscript submissions are welcome.

Dr. Diego Romano Perinelli
Dr. Florentina Lupascu
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
Biomedicines biomedicines	3.9	5.2	2013	15.3 Days	CHF 2600	Submit
Journal of Personalized Medicine jpm	3.0	4.1	2011	16.7 Days	CHF 2600	Submit
Pharmaceuticals pharmaceuticals	4.3	6.1	2004	12.8 Days	CHF 2900	Submit
Pharmaceutics pharmaceutics	4.9	7.9	2009	14.9 Days	CHF 2900	Submit

MDPI Topics is cooperating with Preprints.org and has built a direct connection between MDPI journals and Preprints.org. Authors are encouraged to enjoy the benefits by posting a preprint at Preprints.org prior to publication:

1. Immediately share your ideas ahead of publication and establish your research priority;
2. Protect your idea from being stolen with this time-stamped preprint article;
3. Enhance the exposure and impact of your research;
4. Receive feedback from your peers in advance;
5. Have it indexed in Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (1 paper)

Order results

Content type Publication Date

Result details

Normal Extended Compact

Journals

All Biomedicines JPM Pharmaceuticals Pharmaceutics

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

Error

Oops... you haven't selected anything for export.

Ok

clear

18 pages, 3978 KiB  

Open AccessArticle

Liposomal Drug Delivery against Helicobacter pylori Using Furazolidone and N-Acetyl Cysteine in Augmented Therapy

by Muhammad Irfan Alam, Timothy Paget, Najla Yussuf Moosa, Husein Alghurairy and Amal Ali Elkordy

Pharmaceutics 2024, 16(9), 1123; https://doi.org/10.3390/pharmaceutics16091123 - 26 Aug 2024

Viewed by 1152

Abstract

Helicobacter pylori (H. pylori) infection is a significant global health concern, affecting approximately 50% of the world’s population and leading to gastric ulcers, gastritis, and gastric cancer. The increase in antibiotic resistance has compromised the efficacy of existing therapeutic regimens, necessitating [...] Read more.

Helicobacter pylori (H. pylori) infection is a significant global health concern, affecting approximately 50% of the world’s population and leading to gastric ulcers, gastritis, and gastric cancer. The increase in antibiotic resistance has compromised the efficacy of existing therapeutic regimens, necessitating novel approaches for effective eradication. This study aimed to develop a targeted liposomal drug delivery system incorporating furazolidone and N-acetylcysteine (NAC) to enhance mucopenetration and improve Helicobacter pylori eradication. Liposomes were formulated with furazolidone, NAC, and Pluronic F-127 using a modified reverse-phase evaporation technique. The formulations were categorized based on charge as neutral, negative, and positive and tested for mucopenetration using a modified silicon tube method with coumarin-6 as a fluorescent marker. The encapsulation efficiency and particle size were analyzed using HPLC and an Izon q-nano particle size analyzer. The results indicated that charged liposomes showed a higher encapsulation efficiency than neutral liposomes with Pluronic F-127. Notably, combining furazolidone with 1% NAC achieved complete eradication of H. pylori in 2.5 h, compared to six hours without NAC. The findings of this study suggest that incorporating NAC and Pluronic F-127 into liposomal formulations significantly enhances mucopenetration and antimicrobial efficacy. Full article

(This article belongs to the Topic Personalized Drug Formulations)

►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

 

Error

Oops... you haven't selected anything for export.

Ok

clear

Displaying articles 1-1